Weekly Recap: Relutrigine PDUFA Dec 27, 2026 and 951 RSUs to five hires

Praxis Precision Medicines (NASDAQ:PRAX) said the FDA pushed relutrigine’s PDUFA date to Dec. 27, 2026 after a major amendment but requested no new trials and noted no safety or manufacturing issues; the company also granted 951 RSUs to five non‑executive hires vesting over four years.

Previous Week Recap

• FDA Moves PDUFA Date: Praxis Precision (PRAX) said FDA moved the PDUFA date for relutrigine from Sept 27, 2026 to Dec 27, 2026 after a major amendment; no new trials requested, no safety/manufacturing issues noted.
• PRAX Grants 951 RSUs: Praxis Precision Medicines (PRAX) granted 951 restricted stock units to five new non-executive hires on July 1, 2026. RSUs vest in four equal annual installments, subject to continued employment.

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.